Martin Holst Lange

Money Moves

As of October 2026: Championed the HRS-1596 acquisition

Novo Nordisk will pay China's Hengrui Pharma $300 million upfront to license an experimental weight-loss pill designed for once-weekly use. The $2.6 billion total is a ceiling tied to development and sales milestones; the upfront is the only cash on signing, and it waits on US antitrust clearance.

Updated Oct 1

New Capabilities

As of August 2026: Overseeing denecimig's late-stage program and regulatory filings

People with hemophilia A can bleed for hours from a small cut and bleed inside their joints for no clear reason. Novo Nordisk says its experimental injection, denecimig, kept most patients bleed-free in a long-term trial: about 71% of adults and teens and about 89% of children had zero treated bleeds.

Updated Aug 11